GlobeNewswire

VistaJet Presents Exceptional Travel Experiences for The Collection of Peggy and David Rockefeller

Dela

Three highly personalized programs for art lovers to enhance the most significant philanthropic auction ever presented

 

LONDON, Feb. 08, 2018 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, showcases today three exclusive experiences to enrich the exhibitions and global tour of The Collection of Peggy and David Rockefeller, the most valuable auction of a private collection entirely dedicated to raising funds for philanthropic causes. 

Following the unveiling of early highlights in Hong Kong last November, the global public tour will move to London (February 21 - March 8), Paris (March 16 - 21), Beijing (April 6 - 7), Los Angeles (April 6 - 12) and Shanghai (April 10 - 11), ahead of the final exhibition in New York at Christie's Rockefeller Center from April 28 until the sale on May 7 - 11. With each stop on the pre-sale tour, additional works of art and objects will be revealed.

With 80% of customers regularly investing in art, VistaJet flies some of the world's most prominent collectors. Art has always integrated organically into the brand and as the company continuously strives to provide exceptional and curated experiences for members, anytime and anywhere, VistaJet's three fully customizable The Art of Flying Experiences* will offer exclusive previews, private dinners, lectures and talks, enriching their engagement with the Rockefeller pieces.

The World of Art Experience  will offer customers the opportunity to travel to all of The Collection of Peggy and David Rockefeller exhibitions on-board VistaJet for a private tour of the emblematic collection at each location. By booking this multi-leg journey, VistaJet will transport clients and their art at no additional cost on flights anytime, anywhere** and the experience will also include a year-long membership*** to The Cultivist, the global arts club.

The Direct Experience  will offer any guest flying with VistaJet to any of The Collection of Peggy and David Rockefeller exhibitions in London, Paris, Beijing, Shanghai, Los Angeles or New York, an invitation to receive a complimentary membership to VistaJet Direct worth $10,000. The Direct membership gives clients access to available VistaJet private flights at special rates from any mobile device, through the world's first end-to-end business jet app.

The third exclusive opportunity,  The Rockefeller  Experience , will allow up to 10 guests traveling with VistaJet on one of its iconic silver and red jets to New York, a rare opportunity for a behind the scenes private discovery tour of Kykuit, the historical National Trust landmark of the Rockefeller Estate in Pocantico Hills, before enjoying a Rockefeller-inspired multi-taste feast at an exclusive Upstate New York venue. Guests will then be invited for a personal tour of The Collection of Peggy and David Rockefeller exhibition in New York, and to view the live auction at Christie's New York with leading art experts.

"The Collection of Peggy and David Rockefeller is a unique collection of the finest works of art and objects," said Nina Flohr of VistaJet. "The fact that 100% of the proceeds from the auction of the collection will be donated to charities worldwide is a remarkable philanthropic effort.  We fully support the Rockefellers' commitment to giving back, and our sponsorship is VistaJet's way to facilitate and contribute to the exhibitions, auctions, and ultimately, the Rockefeller family's charitable mission. We are very proud to support their initiative as the key global partner."

The global nature of the auction and exhibitions aligns seamlessly with the VistaJet brand and its global reach. With a fleet of over 70 super-mid and long range identically designed aircraft, VistaJet guarantees availability within 24 hours to its customers, no matter where in the world they are based. The sponsorship of such a landmark collection is a way for VistaJet to support not only the arts, but David and Peggy Rockefeller's philanthropic endeavours.

Sales of The Collection of Peggy and David Rockefeller will be conducted in keeping with David Rockefeller's pledge to direct the majority of his wealth to philanthropy. All the Estate proceeds will be donated to charities, directly benefiting the philanthropic missions that have been maintained by the family for decades.

Find more info on how to enjoy The Collection of Peggy and David Rockefeller with VistaJet at VistaJet.com/TheArtOfFlying

*  Price on request - dependent on origin location, availability, cabin size, airport and slot restrictions..
**  Insurance and transportation terms and conditions apply.
*** Membership to The Cultivist upon application.

VistaJet Press Contacts:
Global and EMERI: Jennifer Farquhar | M: +44 7834 335505 | jennifer.farquhar@vistajet.com 
APAC: Amy Yang | M: +852 9080 3985 | amy.yang@vistajet.com 
USA: Michael Salamanca | M: +1 917 755 3734 | michael.salamanca@vistajet.com 
                         
About VistaJet
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anywhere and at any time.

More VistaJet information and news at vistajet.com

Photos accompanying this announcement are available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/23769297-bca1-4a67-a687-3d839dcb602a 

http://www.globenewswire.com/NewsRoom/AttachmentNg/17a32814-f7d0-4bff-879f-7654a5747449




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum